Zhuhai Trinomab Pharmaceutical Co., Ltd. (SHA:688806)

Market Cap	14.12B
Revenue (ttm)	116.93M +240.2%
Net Income	-510.54M
EPS	-1.31
Shares Out	460.55M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	12,037,504
Open	25.35
Previous Close	25.56
Day's Range	25.35 - 30.67
52-Week Range	14.46 - 52.52
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 29, 2026

About SHA:688806

Zhuhai Trinomab Pharmaceutical Co., Ltd., a biopharmaceutical company, researches, develops, and commercializes therapeutics for infectious diseases and pain-related or autoimmune disorders. The company’s product includes Siltartoxatug Injection (TNM002), a recombinant anti-tetanus toxin monoclonal antibody that neutralizes the toxic effects that target the human neural system. The company was founded in 2015 and is based in Zhuhai, China.

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2015
• Employees: 876
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688806

Financial Performance

In 2025, SHA:688806's revenue was 51.22 million, an increase of 240.23% compared to the previous year's 15.06 million. Losses were -601.32 million, 16.8% more than in 2024.

Data Sources: S&P Global Market Intelligence and Alpha Vantage

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Alpha Vantage.

Last checked:

Oct 8, 2026

Data Sources Report a data error